Israeli Pharma Company Teva Beats Expectations and Raises 2026 Revenue Forecast
How 3 Israeli newsrooms covered this story — translated into English and compared side by side.
By אליהו עמר
First reported by Globes · Jul 29, 2026
What happened
Teva Pharmaceutical Industries reported stronger-than-expected Q2 2026 results, raising its revenue forecast for the year and boosting its stock by 12%. Despite a slight revenue decline due to generic drug sales drops, growth in innovative original drugs like Austedo and Ajovy drove optimism. The company posted a net loss mainly from a one-time acquisition charge but showed a small operational profit excluding this expense.
- 01Teva's Q2 2026 revenue reached $4.1 billion, beating analyst expectations despite a slight year-over-year decline.
- 02Loss of exclusivity on generic cancer drug Revlimid led to lower generic drug sales in the U.S.
- 03Sales of original drugs Austedo, Ajovy, and Uzedy grew significantly, driving revenue growth.
- 04Teva raised its 2026 sales forecast for these three drugs to $3.7 billion and upgraded full-year revenue guidance.
- 05The company reported a $576 million net loss due to a one-time acquisition charge but had a small operational profit excluding it.
- 06Investors responded positively, sending Teva's stock up about 12% at Wall Street opening.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 3 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
